Anshul Maheshwari : Yes, in terms of new surgeon ads, it’s not just the posterior lateral project with TORQ, we’re really focused, as we have been able to last several years through education and engagement to continue to grow that number. And it’s really critical for us as we think about the long term outlook for the business. And based on what we’ve seen thus far, the quarter, we feel pretty confident that we will continue to hit new after surgeon milestones throughout 2023 at the end of each of the quarters. And right now, our expectation is to have that low to mid-teens growth in the fourth quarter of 2023, compared to the fourth quarter of 2022, which as you may recall, Sam was a pretty high watermark to start with the end of last year.
So we feel very good about that. The other piece that also equally important for us is continuing to focus on growing certain overlap. Laura talked about the multiple modalities and treatment types that we’re engaging surgeons with. And we’ve had a lot of success there and we’ve seen a 30% growth in this quarter in after surgeon base for our procedures performed for surgeons have stayed flat. So you’ve actually had surgeons moving up the volume scale as well that have been doing a procedure for a while. So both of those metrics are pointing in the right direction for us.
Samuel Brodovsky: Great, that’s really helpful and appreciate the other color you’ve given on assumptions around price through the second half, which is with the Granite launch going so well. Does that give you a more positive outlook on how you think about price per procedure evolving through 2024 and beyond? Thanks for taking our questions.
Anshul Maheshwari : Yes, no, Sam, on the ASP side. Look, we’re really encouraged by the ASP trends, specifically in the first half, having had two consecutive quarters of year-over-year ASP improvement. And it’s driven by two things, right. The first one is the Granite volume that Laura’s talked about where we’ve seen surgeons, specifically those that do adult deformity procedures using more than two points of fixation, so more than two SI-BONE implants in their procedures. And to some extent, we are also seeing a bit more moderate decline in ASP within the minimally invasive SI joint fusion business, even though we’ve continued to see a move to ASC. And historically, that decline has been in the mid-single digit at the ASC side of service.
But with the increase in the fees in the start of 2023, the team has actually done a great job and working really hard, and in several cases being successful in maintaining that pricing on those contracts. But we also want to acknowledge it’s been only two quarters, right. And while we feel good about some of the reimbursement tailwinds the procedure product mix, we just want to be thoughtful in our not incorporating that upside in the back half the year or at this point too premature to talk 2024.
Operator: Next question will come from Andrew Ranieri of Morgan Stanley.
Andrew Ranieri: Hi, Laura and Anshul. Thanks for taking the questions. Just maybe first on OpEx for [inaudible]. But you’ve a good job year-to-date, leverage is becoming more of an important part of the story. And in your kind of prepared remarks you talked about continued revenue growth and progress towards adjusted EBITDA and cash flow breakeven. So I was hoping you might be able to touch on kind of the latter two parts of these, and maybe kind of what your expectations are for laying the groundwork to eventually achieving these targets of adjusted cash flow and EBITDA breakeven.
